General · EdgepediaSeptember 17, 20269 min read

Μ-opioid receptor

The μ-opioid receptor (MOR) is a seven-transmembrane G-protein-coupled receptor encoded by the human OPRM1 gene (HGNC:8156) and is the principal target of endogenous opioid peptides such as β-endorphin and the enkephalins, as well as of clinically used opioid analgesics.¹ It is the main opioid receptor targeted in pain management and signals primarily by activating the inhibitory Gi pathway.² MOR activation can produce analgesia, respiratory depression, and constipation; repeated or prolonged opioid exposure can lead to tolerance and physical dependence.³

Key fact	Detail
Gene and protein	OPRM1 (6q24-q25) encodes the canonical 7-transmembrane GPCR; some isoforms have only 6 transmembrane domains¹^•³
Signaling	Couples to Gi/o: lowers cAMP, closes calcium channels, opens GIRK channels, inhibits SNARE complexes; GRK phosphorylation recruits β-arrestins for desensitization and internalization⁴^•⁵
Ligand affinities	Carfentanil Ki 2.4×10⁻¹¹ M, sufentanil Ki 1.38×10⁻¹⁰ M, fentanyl pKi 9.2, morphine pKi 9.0, methadone pKi 9.2, buprenorphine pKi 8.8, tramadol Ki 1.6×10⁻⁶ M⁶
Endogenous ligands	[Met]enkephalin pKi 9.2, β-endorphin pKi 9.0, endomorphin-1 pKi 8.3, endomorphin-2 pKi 8.5, dynorphin peptides⁶
Naloxone	Confirmed partial agonist activity of 10% to 30% across BRET assay systems, despite its clinical role as an antagonist⁷
Knockout phenotype	Exon-1 MOR knockout mice lose all systemic morphine and methadone analgesia⁸
OUD medications	Methadone (full agonist), buprenorphine (partial agonist), and naltrexone (antagonist) all act at MOR⁹

Structure and signaling mechanism

The canonical MOR belongs to the superfamily of seven-transmembrane-spanning G-protein-coupled receptors, with an extracellular N-terminus; MOR-1 itself contains four exons that combine to form a wide range of splice variants, and some OPRM1 isoforms have only six transmembrane domains.¹^•⁸

Opioid receptors signal primarily through intracellular G proteins and GPCR kinases. Receptor activation couples to G-protein heterotrimers of Gα, Gβ, and Gγ subunits; the inhibitory Gαi/o lowers cellular cyclic AMP, closes calcium channels, opens GIRK potassium channels, and inhibits SNARE complexes, and the Gβγ subunits act on additional downstream pathways.⁴^•⁵ The β-arrestin pathway, engaged after GRK phosphorylation, regulates signaling through receptor desensitization and internalization.⁵ Interaction of β-arrestin-1 with the receptor core binding site appears less specific and occurs with much lower affinity than binding of Gi.¹⁰

Structural snapshots. Cryo-EM structures of the human MOR–Gi protein complex bound to morphine and to fentanyl, reported in 2022, defined the binding poses of two of the most used opioid drugs; both drugs confer analgesia and side effects through both G-protein and arrestin signaling pathways.¹¹ In 2024, DEER and smFRET measurements showed that nine representative ligands, including naloxone, TRV130, PZM21, buprenorphine, morphine, DAMGO, and lofentanil, each fine-tune the conformational ensemble of the receptor, producing distinctive efficacies and signal bias; with low-efficacy G-protein-biased agonists the TM4–TM6 distance remained mostly in inactive conformations.¹⁰

Ligands

Endogenous peptides. [Met]enkephalin is a full agonist at MOR with pKi 9.2, β-endorphin binds with pKi 9.0, and the endomorphins bind with pKi 8.3 and 8.5; dynorphin peptides also bind.⁶ Endomorphin displays high specificity toward MOR, whereas dynorphins, although activating all opioid receptors except NOPR, have a 100-fold higher potency toward KOR.⁴

Exogenous agonists span weak opioids such as codeine and tramadol and strong opioids including oxycodone, morphine, hydromorphone, meperidine, tapentadol, methadone, fentanyl, sufentanil, and remifentanil.³ IUPHAR-listed potencies include etonitazene EC50 3×10⁻¹¹ M and isotonitazene EC50 5×10⁻¹¹ M in cAMP assays, and mitragynine EC50 5×10⁻¹⁰ M in HEK293T cells expressing human MOR.⁶ PZM21 is listed as a biased agonist with pKi 9.0 and pEC50 8.3 in a Gi/o activation assay.⁶

Antagonists. Naloxone is one of the most common MOR antagonists and is used in overdose.³ Structural work in 2025 nevertheless confirmed partial agonist activity of 10% to 30% for naloxone across BRET assay systems, and showed that naloxone stalls MOR in a "latent" state while loperamide promotes an "engaged" state poised for GDP release.⁷

Physiology and distribution

MORs are the most commonly expressed opioid receptors in the central nervous system, localized in the dorsal horn of the spinal cord (laminae I and II) and in the somatosensory cortex. Activation of presynaptic MORs inhibits release of the excitatory neurotransmitters substance P and glutamate, whereas activation of postsynaptic MORs directly hyperpolarizes postsynaptic neurons.³

Receptors are also expressed in the gastrointestinal tract, where activation slows motility and produces constipation; in the pupil, producing miosis; and in immune cells including CD4+ T lymphocytes, monocytes/macrophages, and neutrophils.³ Acute MOR activation effects include respiratory depression, slowed gastrointestinal motility, nausea, vomiting, constipation, dizziness, pruritus, cough suppression, miosis, hallucinations, dysphoria, and sedation; chronic use leads to tolerance, hyperalgesia, and physical dependence.³

By the numbers

Quantitative anchors for receptor activation come from nucleotide-binding assays on the G protein. MOR in the apo state showed a GDPβS EC50 of 57 ± 14 nM; with loperamide this rose roughly 30-fold to 1.7 ± 0.7 µM, while naloxone gave 89 ± 8.5 nM and DAMGO 0.7 ± 0.16 µM. Agonist efficacy at MOR correlates with decreased GDP affinity promoting GTP exchange, whereas antagonists increase GDP affinity.⁷ The 2024 dynamics study placed ligands on an efficacy scale running from low-efficacy biased agonists (TRV130, PZM21, and buprenorphine) through morphine and the reference agonist DAMGO to the super-efficacy agonists BU72 and lofentanil.¹⁰

Knockout evidence. In exon-1 knockout mice lacking full-length MOR-1 variants, morphine actions were totally lost, as were those of methadone when given systemically, showing that MOR is necessary for these systemic morphine and methadone analgesic effects.⁸ Morphine-6-glucuronide and 6-acetylmorphine, the active metabolite of heroin, retained analgesic activity in these mice, and this residual analgesia persisted in triple knockout mice also lacking δ and κ receptors as well as exon-1 of MOR-1.⁸

Analgesia versus tolerance and respiratory depression: the biased agonism debate

The classic hypothesis rested on β-arrestin2 knockout mice: short-term morphine-induced respiratory suppression and constipation are attenuated in βarr2-KO mice, naloxone-precipitated withdrawal after long-term morphine is attenuated, and β-arrestin2 deletion enhances morphine-induced antinociception and disrupts antinociceptive tolerance.¹² Some opioid ligands preferentially favor Gi signaling over β-arrestin recruitment, and the β-arrestin pathway was proposed to induce adverse effects such as respiratory depression.²

Clinical test. Oliceridine (TRV130), a G-protein-biased MOR agonist with reduced β-arrestin signaling, was approved by the FDA in 2020 and showed decreased risk of constipation and respiratory depression; however, it has abuse liability similar to other opioid analgesics in both human and animal studies.⁵ Fentanyl, methadone, and oxycodone show no differences among genotypes in their ability to induce physical dependence in β-arrestin2 knockout mice, exemplifying agonist-mediated differences in β-arrestin2 function.¹²

Reassessment. A 2024 study proposed that overly strong G-protein signaling (super-efficacy) contributes to respiratory depression and that partial agonists with lower efficacy may provide a safer therapeutic profile, challenging the earlier β-arrestin hypothesis of respiratory depression.¹⁰ The two positions differ on mechanism: the older view attributes respiratory depression to the β-arrestin pathway,² the newer one to G-protein super-efficacy.¹⁰

How it compares with other opioid receptors

The human opioid receptor family comprises MOR, DOR (δ), KOR (κ), and the NOP receptor. MOR has high affinity and modest selectivity for enkephalin-derived peptides; DOR has high affinity for all but dynorphin-derived peptides; KOR preferentially binds dynorphin-derived peptides and the natural product salvinorin A; and NOPR interacts specifically with nociceptin-derived peptides.⁴ The NOP receptor is classified as "opioid-related" rather than opioid because it exhibits a distinct pharmacology.¹³ The Greek letter nomenclature μ, δ, and κ is well established and retained in the current IUPHAR/BPS Guide to Pharmacology (v2025.3), along with the symbols spelled out as mu, delta, and kappa.¹³

Genetic variation and pharmacogenomics

All MOR splice variants designated MOR-1A through MOR-1X are transcribed from the single OPRM1 gene at chromosomal location 6q24-q25; the Ser268→Pro variant receptor significantly reduces coupling efficiency and is less desensitized upon agonist exposure.³

The best-studied variant is the single nucleotide polymorphism Asn40→Asp (A118G). NCBI Gene records that the NM_001008503.2:c.118A>G allele has been associated with opioid and alcohol addiction and variations in pain sensitivity, but that evidence for a causal role is conflicting.¹ Clinical references report associations with increased risk of opioid addiction and altered dose requirements.³ Beyond opioids, MOR has an important role in dependence to other drugs of abuse, such as nicotine, cocaine, and alcohol, via its modulation of the dopamine system.¹

Opioid use disorder pharmacology

Three FDA-approved medications for opioid use disorder target MOR: methadone, a full MOR agonist; buprenorphine, a partial MOR agonist that is also a KOR antagonist and nociceptor receptor agonist; and naltrexone, a MOR and KOR antagonist.⁹ Buprenorphine induces typical opioid effects up to a ceiling, limiting euphoria and respiratory depression, and its very high receptor affinity prevents displacement by full agonists such as heroin; methadone's long half-life allows treatment without destructive behaviors.³

These medications are associated with reduced risk of relapse, overdose deaths, infections, and criminal behavior, and are more cost-effective than no OUD treatment or treatment with no medication; MOR is simultaneously the therapeutic target of these drugs and the target through which heroin and other misused opioids produce rewarding effects.⁹ For the antagonist option, immediate-release naltrexone's utility is limited by poor adherence; the monthly extended-release formulation (XR-NTX) improved treatment retention, and current recommendations call for one week of abstinence before induction because naltrexone triggers acute withdrawal in non-detoxified patients.⁹

What has changed since 2023

Three developments stand out. First, structural biology has moved from single active-state structures to conformational ensembles: the 2024 DEER/smFRET study showed ligand-specific tuning of the TM6 activation pathway across nine ligands,¹⁰ and the 2025 nucleotide-release study delivered 8 structural models and 16 cryo-EM maps of MOR with naloxone or loperamide capturing intermediate conformations along the activation pathway.⁷ Second, a 2024 study proposed that G-protein super-efficacy contributes to respiratory depression, challenging the β-arrestin hypothesis; it also proposed low-efficacy partial agonists as a potentially safer design direction.¹⁰ Third, nomenclature has been continuous: the 2025.3 IUPHAR/BPS database retains the established μ, δ, and κ designations unchanged.¹³

References

Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026; Oct 21, 2026 · Edited: Sep 30, 2026; Oct 15, 2026; Oct 21, 2026